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Introduction
In multicellular organisms, the total number of cells is
a balance between the cell-generating effects of mito-
sis and cell death that is induced through apoptosis. A
disruption of this delicate balance can lead to the
development of cancer [1].
The first descriptions of apoptosis were made over
150 years ago, although the implications for tumor
development were not appreciated until the 1970s.
Natural cell death is a critical part of development of
multicellular organisms, and also counter-balances the
cell generating effects of mitosis [2]. Mitochondria
play a key role in the apoptotic process; their damage,
which involves permeabilization of the outer mito-
chondrial membrane, activates a series of events that
lead to cell death. Of the two proposed signaling path-
ways of apoptosis, i.e. the "extrinsic" and the "intrin-
sic" pathway, the latter is assumed to initiate in mito-
chondria. Its activation involves release of cytochrome
c and other pro-apoptotic factors from the mitochondr-
ial intermembrane space [3]. 
Smac (second mitochondria derived activator of
caspase) and its murine ortholog DIABLO (Direct IAP
binding with Low pI) are mitochondrial proteins
encoded by nuclear DNA which are released into the
cytosol in response to apoptotic stimuli that disrupt the
integrity of mitochondria [4]. Smac/DIABLO partici-
pates in the two main apoptotic pathways, the intrinsic
or mitochondrial pathway [5] and the extrinsic or death
receptor pathway [6]. After apoptotic stimuli, released
smac acts as a dimer in the cytosol, activating caspas-
es by means of sequestering and neutralizing members
of the inhibitor of apoptosis proteins family (IAPs) [7].
Although the expression of smac/DIABLO has
been reported in various cancers, little is known about
its clinical significance in endometrial cancer. The cur-
rent study was designed to evaluate the relationship
between prognosis and smac/DIABLO expression by
clinicopathological analysis of patients with
endometrioid endometrial cancer.
Materials and methods
Patients and clinical samples. A total of 76 patients with
endometrioid endometrial cancers (aged 46-67; median value –
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59.4 years) treated at the Department of Gynecology and Septic
Obstetrics Medical University of Bialystok and the Department of
Gynecology District Hospital in Bialystok between 1999 and 2003
were included in this study. None of the patients had received
chemotherapy, hormonal therapy or radiation therapy prior to sur-
gery. All patients had primary cancers and were receiving first
treatment. Cases selected in the present study showed the same
stage, both clinically and surgically. All tumors were staged
according to the FIGO criteria. 
Clinicopathological information was obtained from medical
charts. Histopathological examination was performed according to
the WHO classification. Representative samples of hysterectomy
specimens were stained with H+E for light microscopic study and
evaluated to confirm a tumor stage and histological type. 
Immunohistochemistry. Tissue sample was frozen in liquid nitro-
gen and maintained at  70°C for Western blot analysis. The pres-
ence of smac/DIABLO protein was estimated by immunoblotting
with an anti-smac/DIABLO mouse monoclonal antibody (BD Bio-
sciences, USA, No. 612244). For Western blot analysis, tissue
samples were suspended in 0.05 M Tris HCl buffer (pH 7.6) in the
ratio 1:3 (wt/vol). The homogenates were prepared with a knife
homogenizer (25000 rpm for 45 seconds at 4°C) and sonicated (20
kHz, 4 × 15 seconds at 4°C). After centrifugation (10000 × g for 15
minutes at 4°C), supernatants were stored at -70°C until measure-
ments were performed. Supernatants were equilibrated with a load-
ing buffer (10% sodium dodecylsulfate [SDS] in Tris HCl [pH
8.0], containing 50% glycerol, 0.1 mM 2-β-mercaptoethanol and
0.1% bromophenol blue) at 50 μg/mL. The mixture was then dena-
tured for 5 minutes at 100°C and samples containing 20 μg of pro-
tein were subjected to electrophoresis. The following molecular
mass standards were used: 39, 29 and 17 kDa (Bio Rad Laborato-
ries, USA). The gels were allowed to equilibrate in 25 mM Tris, 0.2
M L glycine, 20% (vol/vol) methanol for 5 minutes and proteins
were transferred to 0.2 μm pore diameter nitrocellulose mem-
branes at 100 mA for 1 hour. The membranes were then incubated
with one of the following primary antibodies at dilutions 1:500 in
5% dried defatted milk in TBS T (20 mM Tris HCl buffer, pH 7.4;
150 mM NaCl; 0.05% (vol/vol) Tween 20) for 1 hour. Species spe-
cific secondary antibodies were then added at 1:7500 dilutions.
Incubation was continued for 30 minutes with slow shaking. Then,
nitrocellulose membranes were washed with TBS T (5 times for 5
minutes) and treated with Sigma Fast BCIP/NBT reagent (Sigma
Aldrich, Germany). The labeled membranes were photographed,
scanned, and optical density was analyzed using imagining Quan-
tityOne software (Bio Rad Laboratories, USA). 
Ethical issues. Patients were informed and gave their consent for
the study. The protocol was previously approved by the Bioethical
Committee of the Medical University of Bialystok. Follow-up data
were completed until January 2010.
Statistical analysis. Statistical analysis was performed using Sta-
tistica software version 9.0PL (StatSoft, Inc., StatSoft Polska Sp. z
o.o., Poland). A chi-square test was used to evaluate the relation-
ship between categorical variables. Fisher's exact test was used to
determine significance between the two groups. A p-value of <0.05
was considered as statistically significant. In addition, survival
time was calculated from the date of surgery to the date of death
and survival analysis was performed using the Kaplan-Meier
method.
Results
Among 76 patients with endometrioid endometrial
carcinomas, 43 had tumors classified as stage I, 24
patients had tumors classified as stage II, and 9
patients were classified as stage III. The samples were
grouped by histological grade: 41 were classified as
grade 1, 21 were grade 2 and 14 were grade 3 (Table
1). All patients were followed either until death; at a
median follow-up of 60 (range 1-126) months.
Using anti-human smac/DIABLO antibody, pres-
ence of protein was observed in 55 of 76 (72%)
endometrioid endometrial carcinomas (Fig 1). When
the smac/DIABLO expression in the tumor samples
were analyzed, there were significant differences
between histological grade (p<0.001). We found no
significant correlation between protein expression and
clinical tumor stage (p=0.288) (Table 1). 
One-, 5- and 10-year survival rates of patients in
the smac/DIABLO-positive group were 97.8, 95.5 and
95.5%, respectively, what is significantly higher than
survival rates of patients in the smac/DIABLO-nega-
tive group (93.7, 78.1 and 75%, respectively; p=0.043)
(Fig. 2).
679smac/DIABLO in endometrioid endometrial cancer
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(4): 679 (678-681) 
Doi: 10.2478/v10042-010-0091-2
Table 1. Western blot analysis of smac/DIABLO expression com-
pared with stage and grade of examined endometrioid endometri-
al cancer.
Fig. 1. Western blot analysis of smac/DIABLO after 15% sodium
dodecylsulfate-polyacrylamide gel electrophoresis. MW (kDa) –
size marker, samples 1, 2, 3 and 4- tumors with smac/DIABLO
expression; samples 5 and 6 – tumors with absence of protein. 
Discussion
Smac/DIABLO is released from mitochondria into the
cytosol during apoptosis, promoting caspase activation
by neutralizing the inhibition of inhibitor of apoptosis
proteins (IAPs) on caspases. As demonstrated by
Western blot analyses, the expression of smac/
DIABLO is widespread, suggesting its role in the reg-
ulation of apoptosis in a variety of cell types [8, 9]. It
has also been reported that some carcinoma cells over-
express both pro- and antiapoptotic proteins and that a
marginal increase in expression of one proapoptotic
compound can tip the overall balance in favor of cell
death  [10]. 
The level of expression of smac/DIABLO and its
role in prognosis has been studied in relation to sever-
al types of cancers. The protein expressions were seen
to correlate well with poor prognosis in lung cancer
[11], colorectal cancer [12-14], hepatocellular carcino-
ma [15] and sarcomas from various origins [16]. Low
smac/DIABLO expression in renal cell carcinoma pre-
dicted a poor prognosis [17-19]. In bladder cancer it
may be associated with resistance to chemotherapy
[17]. Thus, alteration of apoptosis is essential for can-
cer development and cancer cell death by radiation and
chemotherapy is largely dependent upon apoptosis
[16]. These data partially contradict those of others
that smac/DIABLO expression does not correlate with
stage, grade and prognosis [20,21]. 
In the present report, we have shown for the first
time that smac/DIABLO protein expression correlates
with tumor grade and survival of patients with
endometrioid endometrial cancer. Since smac/DIABLO
expression could be used as a prognostic parameter in
patients with endometrioid endometrial cancer, the
accurate prediction of prognosis may help in selecting
patients for more intensive treatment. We suggest that
detection of smac/DIABLO is a potent prognostic mark-
er in endometrioid endometrial cancer, although its bio-
logical function is still not completely clear.
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